Section Arrow
Quote
PVLA.NASDAQ
- Palvella Therapeutics Inc
Quotes are at least 15-min delayed:2026/07/11 11:34 EDT
Regular Hours
Last
 144.76
-6.28 (-4.16%)
Day High 
150.39 
Prev. Close
151.04 
1-M High
161.38 
Volume 
214.96K 
Bid
144.5
Ask
185
Day Low
140.0601 
Open
150.39 
1-M Low
100 
Market Cap 
2.17B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 145.93 
20-SMA 129.82 
50-SMA 122.34 
52-W High 161.38 
52-W Low 25.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.17/-6.32
Enterprise Value
2.17B
Balance Sheet
Book Value Per Share
16.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.12+0.06+5.66%-- 
RXRXRecursion Pharmaceuticals3.56-0.2-5.32%-- 
VYNEVYNE Therapeutics0.6376-0.0344-5.12%-- 
HUMAHumacyte0.6937-0.0066-0.94%-- 
GOSSGossamer Bio0.1697-0.0053-3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.